Citation

BibTex format

@article{Malekmohammad:2019:10.1186/s12890-019-0954-z,
author = {Malekmohammad, M and Folkerts, G and Kashani, BS and Naghan, PA and Dastenae, ZH and Khoundabi, B and Garssen, J and Mortaz, E and Adcock, IM},
doi = {10.1186/s12890-019-0954-z},
journal = {BMC Pulmonary Medicine},
title = {Exhaled nitric oxide is not a biomarker for idiopathic pulmonary arterial hypertension or for treatment efficacy},
url = {http://dx.doi.org/10.1186/s12890-019-0954-z},
volume = {19},
year = {2019}
}

RIS format (EndNote, RefMan)

TY  - JOUR
AB - BACKGROUND: Idiopathic pulmonary arterial hypertension (IPAH) is a fatal illness. Despite many improvements in the treatment of these patients, there is no unique prognostic variable available to track these patients. The aim of this study was to evaluate the association between fractional exhaled nitric oxide (FeNO) levels, as a noninvasive biomarker, with disease severity and treatment outcome. METHODS: Thirty-six patients (29 women and 7 men, mean age 38.4 ± 11.3 years) with IPAH referred to the outpatient's clinic of Masih Daneshvari Hospital, Tehran, Iran, were enrolled into this pilot observational study. Echocardiography, six-minute walking test (6MWT), FeNO, brain natriuretic peptide (BNP) levels and the functional class of patients was assessed before patients started treatment. Assessments were repeated after three months. 30 healthy non-IPAH subjects were recruited as control subjects. RESULTS: There was no significant difference in FeNO levels at baseline between patients with IPAH and subjects in the control group. There was also no significant increase in FeNO levels during the three months of treatment and levels did not correlate with other disease measures. In contrast, other markers of disease severity were correlated with treatment effect over the three months. CONCLUSION: FeNO levels are a poor non-invasive measure of IPAH severity and of treatment response in patients in this pilot study.
AU - Malekmohammad,M
AU - Folkerts,G
AU - Kashani,BS
AU - Naghan,PA
AU - Dastenae,ZH
AU - Khoundabi,B
AU - Garssen,J
AU - Mortaz,E
AU - Adcock,IM
DO - 10.1186/s12890-019-0954-z
PY - 2019///
SN - 1471-2466
TI - Exhaled nitric oxide is not a biomarker for idiopathic pulmonary arterial hypertension or for treatment efficacy
T2 - BMC Pulmonary Medicine
UR - http://dx.doi.org/10.1186/s12890-019-0954-z
UR - https://www.ncbi.nlm.nih.gov/pubmed/31664957
UR - http://hdl.handle.net/10044/1/74513
VL - 19
ER -